Effects of aldosterone and mineralocorticoid receptor antagonism on cardiac ion channels in the view of upstream therapy of atrial fibrillation

General Physiology and Biophysics

Volumn 30, Issue 1, 2011, Pages 11-19

  Laszlo, Roman ^a   Bentz, Kerstin ^a   Schreieck, Juergen ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Aldosterone; Atrial fibrillation; Atrial remodeling; Mineralocorticoid receptor antagonism; Upstream therapy

Indexed keywords

ALDOSTERONE; CALCIUM CHANNEL L TYPE; CANRENOIC ACID; MINERALOCORTICOID RECEPTOR; SPIRONOLACTONE;

ACTION POTENTIAL; ALDOSTERONE BLOOD LEVEL; CANIDAE; CHINESE HAMSTER; ELECTROPHYSIOLOGY; GENOMICS; GUINEA PIG; HEART ATRIUM; HEART ATRIUM FIBRILLATION; HEART VENTRICLE; HUMAN; MOUSE; NONHUMAN; OXIDATIVE STRESS; RAT; SHORT SURVEY;

ALDOSTERONE ANTAGONISTS; ATRIAL FIBRILLATION; CARDIAC ELECTROPHYSIOLOGY; HEART ATRIA; HEART VENTRICLES; HUMANS; ION CHANNELS; ION TRANSPORT; MALE; RECEPTORS, MINERALOCORTICOID; RENIN-ANGIOTENSIN SYSTEM;

EID: 79953717399     PISSN: 02315882     EISSN: None     Source Type: Journal    
DOI: 10.4149/gpb_2011_01_11     Document Type: Short Survey

References (67)

1. Allessie M., Ausma J., Schotten U. (2002): Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc. Res. 54, 230-246 doi: 10.1016/S0008-6363(02)00258-4
2. Amir O., Amir R. E., Paz H., Mor R., Sagiv M., Lewis B. S. (2008): Aldosterone synthase gene polymorphism as a determinant of atrial fibrillation in patients with heart failure. Am. J. Cardiol. 102, 326-329 doi: 10.1016/j.amjcard.2008.03.063
3. Benitah J. P., Vassort G. (1999): Aldosterone upregulates Ca(2+) current in adult rat cardiomyocytes. Circ. Res. 85, 1139-1145
4. Benitah J. P., Perrier E., Gomez A. M., Vassort G. (2001): Effects of aldosterone on transient outward K+ current density in rat ventricular myocytes. J. Physiol. 537, 151-160 doi:10.1111/j.1469-7793.2001.0151k.x (Pubitemid 33076962)
5. Boixel C., Gavillet B., Rougier J. S., Abriel H. (2006): Aldosterone increases voltage-gated sodium current in ventricular myocytes. Am. J. Physiol. Heart Circ. Physiol. 290, H2257-2266 doi:10.1152/ajpheart.01060.2005
6. Bosch R. F., Scherer C. R., Rub N., Wohrl S., Steinmeyer K., Haase H., Busch A. E., Seipel L., Kuhlkamp V. (2003): Molecular mechanisms of early electrical remodeling: transcriptional downregulation of ion channel subunits reduces I(Ca,L) and I(to) in rapid atrial pacing in rabbits. J. Am. Coll. Cardiol. 41, 858-869 doi: 10.1016/S0735-1097(02)02922-4
7. Briggs A. H., Holland W. C. (1959): Antifibrillatory effects of electrolyte-regulating steroids on isolated rabbit atria. Am. J. Physiol. 197, 1161-1164
8. Caballero R., Moreno I., Gonzalez T., Arias C., Valenzuela C., Delpon E., Tamargo J. (2003): Spironolactone and its main metabolite, canrenoic acid, block human ether-a-go-go-related gene channels. Circulation 107, 889-895 doi:10.1161/01.CIR.0000048189.58449.F7 (Pubitemid 36241049)
9. Cachofeiro V., Miana M., de Las Heras N., Martin-Fernandez B., Ballesteros S., Fernandez-Tresguerres J., Lahera V. (2008): Aldosterone and the vascular system. J. Steroid Biochem. Mol. Biol. 109, 331-335 doi: 10.1016/j.jsbmb.2008.03.005
10. Cai H., Griendling K. K., Harrison D. G. (2003): The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol. Sci. 24, 471-478 doi: 10.1016/S0165-6147(03)00233-5
11. Chai W., Danser A. H. (2006): Why are mineralocorticoid receptor antagonists cardioprotective? Naunyn Schmiedebergs Arch. Pharmacol. 374, 153-162 doi: 10.1007/s00210-006-0107-9 (Pubitemid 44819249)
12. Coraboeuf E., Deroubaix E. (1974): Effect of a spirolactone derivative, sodium canrenoate, on mechanical and electrical activities of isolated rat myocardium. J. Pharmacol. Exp. Ther. 191, 128-138
13. Costa A. R., Torres L. B., Medei E., Ricardo R. A., Franca J. P., Smaili S., Nascimento J. H., Oshiro M. E., Bassani J. W., Ferreira A. T., Tucci P. J. (2009): The negative inotropic action of canrenone is mediated by L-type calcium current blockade and reduced intracellular calcium transients. Br. J. Pharmacol. 158, 580-587 doi: 10.1111/J.1476-5381.2009.00329.X
14. Fuster V., Ryden L. E., Cannom D. S., Crijns H. J., Curtis A. B., Ellenbogen K. A., Halperin J. L., Le Heuzey J. Y., Kay G. N., Lowe J. E. et al. (2006): ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm. Society. Europace 8, 651-745 doi: 10.1093/europace/eul097 (Pubitemid 44472247)
15. Goette A., Hoffmanns P., Enayati W., Meltendorf U., Geller J. C., Klein H. U. (2001): Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation. Am. J. Cardiol. 88, 906-909 doi:10.1016/S0002-9149(01)01905-1
16. Goette A., Bukowska A., Lendeckel U. (2007): Non-ion channel blockers as anti-arrhythmic drugs (reversal of structural remodeling). Curr. Opin. Pharmacol. 7, 219-224 doi: 10.1016/j.coph.2006.09.006
17. Gomez A. M., Rueda A., Sainte-Marie Y., Pereira L., Zissimopoulos S., Zhu X., Schaub R., Perrier E., Perrier R., Latouche C., Richard S., Picot M. C., Jaisser F., Lai F. A., Valdivia H. H., Benitah J. P. (2009): Mineralocorticoid modulation of cardiac ryanodine receptor activity is associated with downregulation of FK506-binding proteins. Circulation 119, 2179-2187 doi:10.1161/CIRCULATIONAHA.108.805804
18. Gomez R., Nunez L., Caballero R., Vaquero M., Tamargo J., Delpon E. (2005): Spironolactone and its main metabolite canrenoic acid block hKv1.5, Kv4.3 and Kv7.1+minK channels. Br. J. Pharmacol. 146, 146-161 doi: 10.1038/sj.bjp.0706302 (Pubitemid 43086104)
19. Hatano S., Yamashita T., Sekiguchi A., Iwasaki Y., Nakazawa K., Sagara K., Iinuma H., Aizawa T., Fu L. T. (2006): Molecular and electrophysiological differences in the L-type Ca2+ channel of the atrium and ventricle of rat hearts. Circ. J. 70, 610-614 doi:10.1253/circj.70.610
20. Heusch G., Schulz R. (2006): [Pathophysiology of the renin-angiotensin- system in atrial fibrillation]. Dtsch. Med. Wochenschr. 131, 817-820 (in Germany) doi:10.1055/s-2006-939853
21. Hool L. C. (2008): Evidence for the regulation of L-type Ca2+ channels in the heart by reactive oxygen species: mechanism for mediating pathology. Clin. Exp. Pharmacol. Physiol. 35, 229-234
22. Issac T. T., Dokainish H., Lakkis N. M. (2007): Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J. Am. Coll. Cardiol. 50, 2021-2028 doi: 10.1016/j.jacc.2007.06. 054
23. Kim Y. H., Lim D. S., Lee J. H., Shim W. J., Ro Y. M., Park G. H., Becker K. G., Cho-Chung Y. S., Kim M. K. (2003): Gene expression profiling of oxidative stress on atrial fibrillation in humans. Exp. Mol. Med. 35, 336-349
24. Korantzopoulos P., Kolettis T., Siogas K., Goudevenos J. (2003): Atrial fibrillation and electrical remodeling: the potential role of inflammation and oxidative stress. Med. Sci. Monit. 9, RA225-229
25. Korantzopoulos P., Kolettis T., Kountouris E., Siogas K. (2004): Atrial remodeling in persistent atrial fibrillation: the potential role of aldosterone. Eur. Heart J. 25, 1086-1087 doi:10.1016/j.ehj.2003.12.033
26. Korantzopoulos P., Kolettis T. M., Galaris D., Goudevenos J. A. (2007): The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. Int. J. Cardiol. 115, 135-143 doi: 10.1016/j.ijcard.2006.04.026
27. Krishnamoorthy S., Lip G. Y. (2009): Renin-angiotensin-aldosterone system blockade in atrial fibrillation and left atrial remodelling. Int. J. Clin. Pract. 63, 982-985 doi:10.1111/j.1742-1241.2009.02083.x
28. Lalevee N., Rebsamen M. C., Barrere-Lemaire S., Perrier E., Nargeot J., Benitah J. P., Rossier M. F. (2005): Aldosterone increases Ttype calcium channel expression and in vitro beating frequency in neonatal rat cardiomyocytes. Cardiovasc. Res. 67, 216-224 doi:10.1016/j.cardiores.2005.05.009
29. Laszlo R., Eick C., Schwiebert M., Schreiner B., Weig H. J., Weretka S., Schreieck J. (2008): Transient outward potassium current in rabbit atrium is depressed after short-time rapid atrial pacing but recovers after a longer pacing period. Gen. Physiol. Biophys. 27, 174-178
30. Laszlo R., Bentz K., Konior A., Eick C., Schreiner B., Kettering K., Schreieck J. (2010): Effects of selective mineralocorticoid receptor antagonism on atrial ion currents and early ionic tachycardia-induced electrical remodelling in rabbits. Naunyn Schmiedebergs Arch. Pharmacol. 382, 347-356 doi:10.1007/s00210-010-0553-2
31. Lemarie C. A., Paradis P., Schiffrin E. L. (2008): New insights on signaling cascades induced by cross-talk between angiotensin II and aldosterone. J. Mol. Med. 86, 673-678 doi: 10.1007/s00109-008-0323-5
32. Lendeckel U., Dobrev D., Goette A. (2010): Aldosterone-receptor antagonism as a potential therapeutic option for atrial fibrillation. Br. J. Pharmacol. 159, 1581-1583 doi: 10.1111/j.1476-5381.2010.00675.x
33. Li D., Shinagawa K., Pang L., Leung T. K., Cardin S., Wang Z., Nattel S. (2001): Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 104, 2608-2614 doi:10.1161/hc4601.099402 (Pubitemid 33104801)
34. Lin P. H., Lee S. H., Su C. P., Wei Y. H. (2003): Oxidative damage to mitochondrial DNA in atrial muscle of patients with atrial fibrillation. Free Radic. Biol. Med. 35, 1310-1318 doi: 10.1016/j.freeradbiomed.2003.07.002
35. Martin-Fernandez B., Miana M., De Las Heras N., Ruiz-Hurtado G., Fernandez-Velasco M., Bas M., Ballesteros S., Lahera V., Cachofeiro V., Delgado C. (2009): Cardiac L-type calcium current is increased in a model of hyperaldosteronism in the rat. Exp. Physiol. 94, 675-683 doi: 10.1113/expphysiol.2009.047688
36. McManus F., McInnes G. T., Connell J. M. (2008): Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist. Nat. Clin. Pract. Endocrinol. Metab. 4, 44-52 doi: 10.1038/ncpendmet0676
37. Milliez P., Girerd X., Plouin P. F., Blacher J., Safar M. E., Mourad J. J. (2005): Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J. Am. Coll. Cardiol. 45, 1243-1248 doi:10.1016/j.jacc.2005.01.015
38. Muto T., Ueda N., Opthof T., Ohkusa T., Nagata K., Suzuki S., Tsuji Y., Horiba M., Lee J. K., Honjo H., Kamiya K., Kodama I., Yasui K. (2007): Aldosterone modulates I(f) current through gene expression in cultured neonatal rat ventricular myocytes. Am. J. Physiol. Heart Circ. Physiol. 293, H2710-2718 doi: 10.1152/ajpheart.01399.2006
39. Nattel S., Matthews C., De Blasio E., Han W., Li D., Yue L. (2000): Dose-dependence of 4-aminopyridine plasma concentrations and electrophysiological effects in dogs : potential relevance to ionic mechanisms in vivo. Circulation 101, 1179-1184 (Pubitemid 30146621)
40. Nattel S., Burstein B., Dobrev D. (2008): Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ. Arrhythm. Electrophysiol. 1, 62-73 doi:10.1161/CIRCEP.107.754564
41. Nerbonne J. M., Kass R. S. (2005): Molecular physiology of cardiac repolarization. Physiol. Rev. 85, 1205-1253 doi:10.1152/physrev.00002.2005
42. Neuman R. B., Bloom H. L., Shukrullah I., Darrow L. A., Kleinbaum D., Jones D. P., Dudley S. C. Jr. (2007): Oxidative stress markers are associated with persistent atrial fibrillation. Clin. Chem. 53, 1652-1657 doi:10.1373/clinchem.2006.083923
43. Ouvrard-Pascaud A., Sainte-Marie Y., Benitah J. P., Perrier R., Soukaseum C., Cat A. N., Royer A., Le Quang K., Charpentier F., Demolombe S., Mechta-Grigoriou F., Beggah A. T., MaisonBlanche P., Oblin M. E., Delcayre C., Fishman G. I., Farman N., Escoubet B., Jaisser F. (2005): Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation 111, 3025-3033 doi:10.1161/CIRCULATIONAHA.104.503706 (Pubitemid 40847778)
44. Ovaert P., Elliott J., Bernay F., Guillot E., Bardon T. (2010): Aldosterone receptor antagonists-how cardiovascular actions may explain their beneficial effects in heart failure. J. Vet. Pharmacol. Ther. 33, 109-117 doi:10.1111/j.1365-2885.2009.01122.x
45. Pei D. A., Li L., Xu Z. Y., Zou L. J., Zhang B. R., Huang S. D., Hao J. H., Wang Z. N., Lu F. L. (2007): Expression of mineralocorticoid receptor and 11 -beta-hydroxysteroid dehydrogenase type 2 in human atria during chronic atrial fibrillation: study of 25 cases. Zhonghua Yi Xue Za Zhi 87, 816-819 (in Chinese)
46. Perrier E., Kerfant B. G., Lalevee N., Bideaux P., Rossier M. F., Richard S., Gomez A. M., Benitah J. P. (2004): Mineralocorticoid receptor antagonism prevents the electrical remodeling that precedes cellular hypertrophy after myocardial infarction. Circulation 110, 776-783 doi:10.1161/01.CIR.0000138973. 55605.38 (Pubitemid 39096003)
47. Perrier R., Richard S., Sainte-Marie Y., Rossier B. C., Jaisser F., Hummler E., Benitah J. P. (2005): A direct relationship between plasma aldosterone and cardiac L-type Ca2+ current in mice. J. Physiol. 569, 153-162 doi:10.1113/jphysiol.2005.092692 (Pubitemid 41701382)
48. Pitt B., Zannad F., Remme W. J., Cody R., Castaigne A., Perez A., Palensky J., Wittes J. (1999): The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341, 709-717
49. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., Bittman R., Hurley S., Kleiman J., Gatlin M. (2003a): Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348, 1309-1321 doi: 10.1056/NEJMoa030207
50. Pitt B., Stier C. T., Jr., Rajagopalan S. (2003b): Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease. J. Renin Angiotensin Aldosterone Syst. 4, 164-168 doi: 10.3317/jraas.2003.025 (Pubitemid 37407163)
51. Qu Y., Rogers J., Tanada T., Scheuer T., Catterall W. A. (1994): Modulation of cardiac Na+ channels expressed in a mammalian cell line and in ventricular myocytes by protein kinase C. Proc. Natl. Acad. Sci. U.S.A. 91, 3289-3293 doi:10.1073/pnas.91.8.3289
52. Rozanski G. J., Xu Z. (2002): A metabolic mechanism for cardiac K+ channel remodelling. Clin. Exp. Pharmacol. Physiol. 29, 132-137 doi: 10.1046/j.1440-1681.2002.03618.x
53. Schram G., Pourrier M., Melnyk P., Nattel S. (2002): Differential distribution of cardiac ion channel expression as a basis for regional specialization in electrical function. Circ. Res. 90, 939-950 doi:10.1161/01.RES.0000018627.89528.6F
54. Shimoni Y., Chen K., Emmett T., Kargacin G. (2008): Aldosterone and the autocrine modulation of potassium currents and oxidative stress in the diabetic rat heart. Br. J. Pharmacol. 154, 675-687 doi:10.1038/bjp.2008.114
55. Shroff S. C., Ryu K., Martovitz N. L., Hoit B. D., Stambler B. S. (2006): Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure. J. Cardiovasc. Electrophysiol. 17, 534-541 doi:10.1111/J.1540-8167. 2006.00372.X
56. Stier C. T., Jr., Chander P. N., Rocha R. (2002): Aldosterone as a mediator in cardiovascular injury. Cardiol. Rev. 10, 97-107 doi: 10.1097/00045415-200203000-00008
57. Struthers A. D., MacDonald T. M. (2004): Review of aldosterone- and angiotensin Il-induced target organ damage and prevention. Cardiovasc. Res. 61, 663-670 doi:10.1016/j.cardiores.2003.11.037
58. Takemoto M., Node K., Nakagami H., Liao Y., Grimm M., Takemoto Y., Kitakaze M., Liao J. K. (2001): Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J. Clin. Invest. 108, 1429-1437
59. Tillmann H. C., Schumacher B., Yasenyev O., Junker M., Christ M., Feuring M., Wehling M. (2002): Acute effects of aldosterone on intracardiac monophasic action potentials. Int. J. Cardiol. 84, 39-40 doi:10.1016/S0167-5273(02)00115-8
60. Van Wagoner D. R. (2008): Oxidative stress and inflammation in atrial fibrillation: role in pathogenesis and potential as a therapeutic target. J. Cardiovasc. Pharmacol. 52, 306-313 doi:10.1097/FJC.0b013e31817f9398
61. Wagner M., Rudakova E., Volk T. (2008): Aldosterone-induced changes in the cardiac L-type Ca(2+) current can be prevented by antioxidants in vitro and are absent in rats on low salt diet. Pflugers Arch. 457, 339-349 doi: 10.1007/s00424-008-0518-1
62. Wehling M., Spes C. H., Win N., Janson C. P., Schmidt B. M., Theisen K., Christ M. (1998): Rapid cardiovascular action of aldosterone in man. J. Clin. Endocrinol. Metab. 83, 3517-3522 doi:10.1210/jc.83.10.3517
63. Wijffels M. C., Kirchhof C. J., Dorland R., Allessie M. A. (1995): Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 92, 1954-1968
64. Workman A. J., Kane K. A., Rankin A. C. (2008): Cellular bases for human atrial fibrillation. Heart Rhythm 5, S1-6 doi: 10.1016/j.hrthm.2008.01.016
65. Wozakowska-Kaplon B., Bartkowiak R., Janiszewska G (2010). A Decrease in Serum Aldosterone Level is Associated with Maintenance of Sinus Rhythm after Successful Cardioversion of Atrial Fibrillation. Pacing Clin. Electrophysiol. 33, 561-565 doi:10.1111/j.1540-8159.2009.02673.x
66. Zannad F. (1991): Vascular and cardiac actions of aldosterone and spironolactone. Z Kardiol 80 (Suppl. 7), 103-105
67. Zhao J., Li J., Li W., Li Y., Shan H., Gong Y., Yang B (2010). Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing. Br. J. Pharmacol. 159, 1584-1594 doi:10.1111/j.1476-5381.2009.00551.x